StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Ashish Bahety, Profitmart Securities

BUYDr. Reddy's Laboratories Limited

byAshish Bahety, Profitmart SecuritiesHorizon: NA (inferred Swing (≤2wk))25 Jun 2026via CNBC Awaaz.

Entry₹1,350.5Inferred
Target₹1,420
Total upside +5.15% (call closed)
Stop lossNot given
At expiry₹1,2689 Jul 2026, 3:30 pm
Expired-6.11%
Follow Ashish Bahety for new calls(34% target hit, 207 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 116 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 11:16 pm IST
3 supporting1 opposing
Supports the BUY call (3)

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·29 Jun · 1w ago

Dr. Reddy's Laboratories Limited announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States.

NSE · Press Release·13 Jun · 4w ago

(opens in new tab)

Dr. Reddy's Laboratories Ltd. has launched Bosutinib Tablets 400mg.

BSE · Company Update·13 Jun · 4w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

1 advisor has an active short-term SELL call on this stock

Advisor consensus · adjacent horizon·15 Apr · 3mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.